Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Go back to Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury| Raptor Technology Group, Inc. (NASDAQ: RAPT) | Delayed: 58.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.02 | 52 Week High | $0.02 | |||
| Open | $58.02 | 52 Week Low | $0.00 | |||
| Day High | $58.02 | P/E | N/A | |||
| Day Low | $58.02 | EPS | $0.00 | |||
| Volume | 2,691,529 | |||||
